Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole

scientific article published on 5 May 2012

Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1019090133
P356DOI10.1007/S10637-012-9829-3
P698PubMed publication ID22555773

P50authorJos BeijnenQ23771643
P2093author name stringG Edwards
J H M Schellens
J Wanders
L A Devriese
F Peng
S Marchetti
A Jenner
L Reyderman
M Mergui-Roelvink
W Copalu
P2860cites workEribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instabilityQ24610709
Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphaseQ24657514
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaQ27860904
In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin BQ28202233
The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growthQ28261808
Prediction of creatinine clearance from serum creatinineQ29615603
Toxicity and response criteria of the Eastern Cooperative Oncology GroupQ29619399
Modulation of irinotecan metabolism by ketoconazoleQ33183940
Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxelQ33202430
Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibitionQ33834603
Interaction of common azole antifungals with P glycoproteinQ34104641
P-glycoprotein related drug interactions: clinical importance and a consideration of disease statesQ37732337
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabineQ37777290
Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancerQ42653377
A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.Q45976166
Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.Q45976200
Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxaneQ46059531
Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4.Q46353411
The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development.Q46616124
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.Q52846107
Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumorsQ82276332
Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cellsQ82912927
Validation of high-performance liquid chromatography-tandem mass spectrometry assays for the quantification of eribulin (E7389) in various biological matricesQ83766973
P433issue2
P921main subjectpharmacokineticsQ323936
eribulin mesylateQ27882076
P304page(s)381-389
P577publication date2012-05-05
P1433published inInvestigational New DrugsQ2312231
P1476titleEribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole
P478volume31

Reverse relations

cites work (P2860)
Q51301390A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors.
Q37637936Eribulin -- a review of preclinical and clinical studies.
Q26799328Eribulin in Cancer Treatment
Q38722807Eribulin in advanced liposarcoma and leiomyosarcoma
Q39120142Eribulin in non-small cell lung cancer: challenges and potential strategies.
Q54694130Eribulin mesylate in breast cancer.
Q35699382Eribulin mesylate in the treatment of metastatic breast cancer
Q26782784Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine's Tool Box
Q34683835Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program
Q42715686Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment
Q36629243Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin
Q47111016Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study
Q37161899Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia
Q51091552Population pharmacometric analyses of eribulin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes
Q37356164Potential clinical applications of halichondrins in breast cancer and other neoplasms.

Search more.